Preclinical rodent toxicity studies for long term use of ceftriaxone

by Elena Ratti, James D. Berry, David J. Greenblatt, Lorena Loci, Amy Swartz Ellrodt, Jeremy M. Shefner, Merit E. Cudkowicz
Published 2015-01-01

Evaluation of Amyotrophic Lateral Sclerosis-Induced Muscle Degeneration Using Magnetic Resonance-Based Relaxivity Contrast Imaging (RCI)

by Sudarshan Ragunathan, Laura C. Bell, Natenael Semmineh, Ashley M. Stokes, Jeremy M. Shefner, Robert Bowser, Shafeeq Ladha, C. Chad Quarles
Published 2021-05-01

Reply to: Frequent self‐assessments in ALS clinical trials: Worthwhile or an unnecessary burden?

by Seward B. Rutkove, Pushpa Narayanaswami, Visar Berisha, Julie Liss, Shira Hahn, Kerisa Shelton, Kristin Qi, Sarbesh Pandeya, Jeremy M. Shefner
Published 2020-10-01

Improved ALS clinical trials through frequent at‐home self‐assessment: a proof of concept study

by Seward B. Rutkove, Pushpa Narayanaswami, Visar Berisha, Julie Liss, Shira Hahn, Kerisa Shelton, Kristin Qi, Sarbesh Pandeya, Jeremy M. Shefner
Published 2020-07-01

Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS

by Jerònia Lladó, Christine Haenggeli, Andrea Pardo, Victor Wong, Leah Benson, Carol Coccia, Jeffrey D. Rothstein, Jeremy M. Shefner, Nicholas J. Maragakis
Published 2006-01-01

Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis

by Hagit Goldshtein, Alexandre Muhire, Virginie Petel Légaré, Avital Pushett, Ron Rotkopf, Jeremy M. Shefner, Randall T Peterson, Gary A. B. Armstrong, Niva Russek‐ Blum
Published 2020-10-01

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis.

by James D Berry, Jeremy M Shefner, Robin Conwit, David Schoenfeld, Myles Keroack, Donna Felsenstein, Lisa Krivickas, William S David, Francine Vriesendorp, Alan Pestronk, James B Caress, Jonathan Katz, Ericka Simpson, Jeffrey Rosenfeld, Robert Pascuzzi, Jonathan Glass, Kourosh Rezania, Jeffrey D Rothstein, David J Greenblatt, Merit E Cudkowicz, Northeast ALS Consortium
Published 2013-01-01

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

by Michael J. Brownstein, Neal G. Simon, Jeffrey D. Long, Jon Yankey, Hilda T. Maibach, Merit Cudkowicz, Christopher Coffey, Robin A. Conwit, Codrin Lungu, Karen E. Anderson, Steven M. Hersch, Dixie J. Ecklund, Eve M. Damiano, Debra E. Itzkowitz, Shifang Lu, Marianne K. Chase, Jeremy M. Shefner, Andrew McGarry, Brenda Thornell, Catherine Gladden, Michele Costigan, Padraig O’Suilleabhain, Frederick J. Marshall, Amy M. Chesire, Paul Deritis, Jamie L. Adams, Peter Hedera, Kelly Lowen, H. Diana Rosas, Amie L. Hiller, Joseph Quinn, Kellie Keith, Andrew P. Duker, Christina Gruenwald, Angela Molloy, Cara Jacob, Stewart Factor, Elaine Sperin, Danny Bega, Zsazsa R. Brown, Lauren C. Seeberger, Victor W. Sung, Melanie Benge, Sandra K. Kostyk, Allison M. Daley, Susan Perlman, Valerie Suski, Patricia Conlon, Matthew J. Barrett, Stephanie Lowenhaupt, Mark Quigg, Joel S. Perlmutter, Brenton A. Wright, Elaine Most, Guy J. Schwartz, Jessica Lamb, Rosalind S. Chuang, Carlos Singer, Karen Marder, Joyce A. Moran, John R. Singleton, Meghan Zorn, Paola V. Wall, Richard M. Dubinsky, Carolyn Gray, Carolyn Drazinic
Published 2020-11-01